Catalyst Capital Advisors’s Genmab GMAB Stock Holding History

Catalyst Capital Advisors’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-315	Closed	-$6K	–	347
2019 Q3	$6K	Buy	+315	New	+$6.2K	﹤0.01%	382

Other funds holding GMAB

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Catalyst Capital Advisors's GMAB Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Genmab (GMAB) in Q4 2019, closing a stake of 315 shares — an estimated $6K sold.

Catalyst Capital Advisors first reported a position in GMAB in Q3 2019 and held it in 1 quarter. The position peaked at $6K in Q3 2019. 133 funds tracked by Wall St. Rank hold GMAB as of Q4 2019.

Catalyst Capital Advisors reported no remaining Genmab position as of Q4 2019 after selling out during the quarter.
Catalyst Capital Advisors sold 315 Genmab shares in Q4 2019, an estimated $6K.
Catalyst Capital Advisors first reported a position in Genmab in Q3 2019 and held it in 1 quarter.
Catalyst Capital Advisors's Genmab position peaked at $6K in Q3 2019.
133 funds tracked by Wall St. Rank held Genmab as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.